ERLINA 25/5MG TAB (14s)

ERLINA 25/5mg Tablets (14s) combine empagliflozin 25mg and linagliptin 5mg, designed for the effective management of type 2 diabetes mellitus. This dual-action therapy works by enhancing insulin secretion, reducing glucose production in the body, and promoting the elimination of excess sugar through urine. ERLINA helps achieve better blood sugar control, supports cardiovascular health, and assists in maintaining healthy body weight when used alongside proper diet and exercise.

Uses:

• Controls high blood glucose levels in type 2 diabetes.

• Reduces the risk of diabetic heart and kidney complications.

• Improves insulin sensitivity and overall glycemic control.

Benefits:

• Dual mechanism for comprehensive diabetes management.

• Helps in weight management and supports metabolic balance.

• Low risk of hypoglycemia when not combined with insulin or sulfonylureas.

• Once-daily tablet ensures convenience and better compliance.

Side Effects:

• Common: Increased urination, thirst, nausea, or nasal congestion.

• Occasional: Urinary tract or genital infections, low blood sugar (with other antidiabetics), or digestive upset.

• Rare: Allergic reactions or dehydration if fluid intake is insufficient.